Editas Medicine
EDIT
151 hedge funds and large institutions have $934M invested in Editas Medicine in 2017 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 46 increasing their positions, 25 reducing their positions, and 17 closing their positions.
212% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 17
84% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 25
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
34% more capital invested
Capital invested by funds: $698M → $934M (+$237M)
30% more funds holding
Funds holding: 116 → 151 (+35)
0.03% less ownership
Funds ownership: 69.01% → 68.97% (-0.03%)
32% less call options, than puts
Call options by funds: $13.5M | Put options by funds: $20M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.9M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$10.7M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.96M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$6.02M |
| 4 |
GAM
Greenwoods Asset Management
Grand Cayman,
Cayman Islands
|
-$4.37M |
| 5 |
PP
Peconic Partners
New York
|
-$3.56M |
EDIT Hedge Fund Activity: Q4 2017 in Review
151 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2017, worth a combined $934M — up 34% from $698M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new EDIT positions and 17 closed out — a net gain of 36 holders — while 46 added to existing stakes and 25 trimmed.
The largest buyer was State Street, adding an estimated $13.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.5M.
- 151 institutional investors held Editas Medicine (EDIT) as of Q4 2017, up from 116 in Q3 2017.
- Funds reported $934M of Editas Medicine stock for Q4 2017, up 34% quarter-over-quarter.
- 53 funds opened new Editas Medicine positions in Q4 2017 and 17 closed out, a net change of +36 holders.
- The largest Editas Medicine buyer in Q4 2017 was State Street, an estimated $13.9M added.
- The largest Editas Medicine seller in Q4 2017 was T. Rowe Price Associates, an estimated $8.5M sold.
Based on aggregated 13F filings for Q4 2017.